Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP
Status:
Not yet recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, multicenter, double-blind, non-inferiority study to evaluate
the efficacy and safety of cefepime-taniborbactam compared to meropenem in patients ≥ 18
years of age with ventilated HABP or VABP.
Phase:
Phase 3
Details
Lead Sponsor:
Venatorx Pharmaceuticals, Inc.
Collaborator:
Biomedical Advanced Research and Development Authority